Emerging problem to health care workers in form of virus and fungus combo: a tertiary care centre experience

Vimla Beniwal, Surender kumar Beniwal, Jaishri Murli Manoher, Hari Ram Jat


Background: Rhino-orbital-cerebral mucormycosis has reached epidemic proportion during second wave of COVID-19 pandemic in India. In this study we aimed to understand the demographics, presentation, temporal sequence, risk factors and outcomes to undertake measures for prevention and treatment and benefit of administering liposomal amphotericin via retrobulbar injection in addition to systemic antifungals in the setting of rhino-orbital-mucormycosis.

Methods: Study of patients with COVID-19-associated mucormycosis managed or co-managed by ophthalmologists in our centre from April 2021 to June 2021.

Results: Male predominance and more than 75% associated with COVID-19 infection. Common risk factors associated were DM and corticosteroids use. Unilateral involvement was common (82.4%). Most common primary symptom and sign of ROCM is orbital/facial pain (68.4%) and ptosis (84.2 %) respectively. retro bulbar amphotericin B injections had slight improvement in vision (25%), ptosis (37.5%) and extra ocular movement (25%) with few complications. Surgical management were PNS debridement (42.1%), exenteration added in 17.5 % and with above procedure additional maxillectomy needed in 14%. 22.8 % cases were succumbed by disease while 40.1 % of live patients needed orbital exenteration.

Conclusions: ROCM has visible signs and symptoms, help us in early diagnosis as compared to mucormycosis at other anatomical sites and should be known to all ophthalmologists. Early diagnosis by involving root level health worker and creation of standard treatment guideline on emerging heath problem is an urgent need.



Rhino-orbital-cerebral mucormycosis, COVID-19, DKA

Full Text:



Mcnulty JS. Rhinocerebralmucormycosis: predisposing factors. Laryngoscope. 1982;92:1140-43.

Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556LP-69.

Pillsbury HC, Fischer ND. Rhinocerebralmucor-mycosis. Arch Otolaryngol. 1977;103:600-4.

Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and Clinical Manifestations of Mucormycosis. Clin Infect Dis. 2012;54:S23-34.

Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID‑19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021.

Chander J, Kaur M, Singla N, Punia RP, Singhal SK, Attri AK, et al. Mucormycosis: Battle with the deadly enemy over a five‑year period in India. J Fungi 2018;4:46.

Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi. 2019;5:26.

Idf Diabetes Atlas. 2019. Available at: Accessed on 27 May 2021.

Rawson TM, Moore LS, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal coinfection in individuals with coronavirus: A rapid review to support COVID‑19 antimicrobial prescribing. Clin Infect Dis. 2020;71:2459‑68.

Song G, Liang G, Liu W. Fungal co‑infections associated with global COVID‑19 pandemic: A clinical and diagnostic perspective from China. Mycopathologia. 2020;31:1‑8.

Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis. 2009; 15:1395-401.

Ma N, Li P, Wang X, Yu Y, Tan X, Chen P, et al. Ocular manifestations and clinical characteristics of children with laboratory-confirmed COVID-19 in Wuhan, China. JAMA Ophthalmol. 2020;138:1079-86.

Tisdale AK, Chwalisz B. Neuro-ophthalmic manifestations of coronavirus disease 19. Curr Opin Ophthalmol. 2020;31:489-94.

Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2020;42:264.e8.

Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020;12:e10726.

Dallalzadeh LO, Ozzello DJ, Liu CY, Kikkawa DO, Korn BS. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. Orbit. 2021;23:1-4.

Fouad YA, Abdelaziz TT, Askoura A, Saleh MI, Mahmoud MS, Ashour D, et al. Spike in rhino-orbital-cerebral mucormycosis cases presenting to a tertiary care center during the COVID-19 Pandemic Front Med. 2021;8:645270.

Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A, Gangneux JP, et al. The Emergence of COVID‑19 associated mucormycosis: analysis of cases from 18 countries. Available at:https://papers. Accessed on 20 May 2021.

Sen M, Honavar SG, Bansal R, Sengupta S, Rao R, Kim U, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India – Collaborative OPAI-IJO Study on Mucormycosis in COVID‑19 (COSMIC), Report 1. Indian J Ophthalmol. 2021;69:1670-92.

Kayina CA, Haritha D, Soni L, Behera S, Nair PR, Gouri M, et al. Epidemiological and clinical characteristics and early outcome of COVID‑19 patients in a tertiary care teaching hospital in India: A preliminary analysis. Indian J Med Res. 2020;152:100‑4.

Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid‑19. N Engl J Med. 2021;384:693704.

Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003;362:1828‑38.

Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood 2011;118:1216‑24.

Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47:193‑9.

Kothandaraman N, Rengaraj A, Xue B, Yew WS, Velan SS, Karnani N, et al. COVID‑19 endocrinopathy with hindsight from SARS. Am J Physiol Endocrinol Metab. 2021;320:E139‑50.

Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DC, et al. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta‑analysis of case reports. Clin Microbiol Infect. 2019;25:26‑34.

Bala K, Chander J, Handa U, Punia RS, Attri AK. A prospective study of mucormycosis in north India: Experience from a tertiary care hospital. Med Mycol. 2015;53:248‑57.

John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID‑19 converge: The perfect storm for mucormycosis. J Fungi. 2021;7:298.

Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections:clinical efficacy and gaps in coverage. Clin Infect Dis. 2006;43:1060.

Sun QN, Fothergill AW, McCarthy DI, et al. In vitro activities of Posaconazole, itraconazole, voticonazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 2002;46:1581.

Van Burik JA, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006:42:e61.

Lee AS, Lee PW, Allworth A, Smith T, Sullivan TJ. Orbital mycoses in an adult subtropical population. Eye. 2020;34:1640‑7.

Hirabayashi KE, Kalin‑Hajdu E, Brodie FL, Kersten RC, Russell MS, Vagefi MR. Retrobulbar injection of amphotericin B for orbital mucormycosis. Ophthalmic Plast Reconstr Surg. 2017;33:e94‑7.

Safi M, Ang MJ, Patel P, Silkiss RZ. Rhino‑orbital‑cerebral mucormycosis (ROCM) and associated cerebritis treated with adjuvant retrobulbar amphotericin B. Am J Ophthalmol Case Rep. 2020;19:100771.

Songu M, Unlu HH, Gunhan K, Ilker SS, Nese N. Orbital exenteration: A dilemma in mucormycosis presented with orbital apex syndrome. Am J Rhinol. 2008;22:98‑103.

Pelton RW, Peterson EA, Patel BC, Davis K. Successful treatment of rhino‑orbital mucormycosis without exenteration: The use of multiple treatment modalities. Ophthalmic Plast Reconstr Surg. 2001;17:62‑6.